Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Last updated: March 28, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Active - Recruiting

Phase

3

Condition

Urticaria

Hives (Urticaria)

Treatment

Placebo to remibrutinib

Placebo to omalizumab

Omalizumab

Clinical Study ID

NCT06042478
CLOU064A2304
2022-000518-32
2022-502161-19-00
  • Ages 18-100
  • All Genders

Study Summary

The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH).

The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and female adult participants ≥18 years of age at the time of signing theinformed consent.

  • CSU duration for ≥ 6 months prior to screening.

  • Diagnosis of CSU inadequately controlled by second generation H1-AH at the time ofrandomization, defined as:

  • The presence of itch and hives for ≥6 consecutive weeks prior to screening, despitethe use of second-generation H1-AH during this time period.

  • UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0-

  1. ≥ 6 during the 7 days prior to randomization (Day 1).
  • Documentation of hives within three months before randomization.

  • Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for theduration of the study and adhere to the study protocol.

  • Participants must not have had more than one missing UPDD entry (either morning orevening) in the 7 days prior to randomization (Day 1).

Exclusion

Exclusion Criteria:

  • Prior exposure to ligelizumab, omalizumab and other biologics with any effect inCSU, including anti-IgE therapies.

  • Significant bleeding risk or coagulation disorders.

  • History of gastrointestinal bleeding.

  • Requirement for anti-platelet or anti-coagulant medication.

  • History or current hepatic disease.

  • Evidence of clinically significant cardiovascular, neurological, psychiatric,pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders,gastrointestinal disease or immunodeficiency that, in the investigator's opinion,would compromise the safety of the participant, interfere with the interpretation ofthe study results or otherwise preclude participation or protocol adherence of theparticipant.

  • Evidence of helminthic parasitic infection as evidenced by stools being positive fora pathogenic organism according to local guidelines.

  • Documented history of anaphylaxis.

  • Pregnant or nursing (lactating) women.

Study Design

Total Participants: 468
Treatment Group(s): 4
Primary Treatment: Placebo to remibrutinib
Phase: 3
Study Start date:
November 15, 2023
Estimated Completion Date:
June 25, 2027

Study Description

The study consists of 4 periods, and the total study duration is up to 112 weeks. Approximately 468 adult participants with CSU are expected to be randomized in the study.

Screening period: A screening period of up to 4 weeks will allow for the assessment of eligibility, determination of baseline disease activity and wash-out of prohibited medications.

Core Phase Treatment Period (52 weeks):

The treatment period will be double-dummy and double-blind, with placebo injections matching omalizumab 300 mg s.c. given to participants in the remibrutinib arm and placebo tablets matching remibrutinib 25 mg given to participants in the omalizumab arm (double-dummy). At the randomization visit, eligible participants will be randomized to one of four treatment arms.

Extension Phase Treatment Period (52 weeks): Optional open-label extension where patients receive treatment with open-label remibrutinib 25 mg, for 52 weeks.

Follow-up period:

For patients that do not enter the extension phase, there will be a 16-week, treatment-free, safety follow-up period.

Patients that enter extension phase will have a 4-week treatment-free safety follow-up period at the end of the extension phase.

All participants will be on a stable, local label-approved standard dose of a second-generation H1-AH ("background therapy") throughout the entire core phase (starting a minimum of 7 days prior to randomization until the end of the core phase).

In addition, to treat unbearable symptoms of CSU flare-ups, participants will be allowed to use a different second-generation H1-AH on an as-needed basis ("rescue therapy").

Connect with a study center

  • Novartis Investigative Site

    Rosario, Santa Fe S2000DBS
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Bahia Blanca, B8000JRB
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Caba, C1012AAY
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Capital Federal, C1023AAB
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Mendoza, 5500
    Argentina

    Active - Recruiting

  • Novartis Investigative Site

    Woolloongabba, Queensland 4102
    Australia

    Active - Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria 3004
    Australia

    Active - Recruiting

  • Novartis Investigative Site

    Porto Alegre, RS 90560 030
    Brazil

    Active - Recruiting

  • Novartis Investigative Site

    Santo Andre, SP 09060-870
    Brazil

    Active - Recruiting

  • Novartis Investigative Site

    Sorocaba, SP 18040-425
    Brazil

    Active - Recruiting

  • Novartis Investigative Site

    Alphaville Barueri, Sao Paulo 06454010
    Brazil

    Active - Recruiting

  • Novartis Investigative Site

    Sofia, 1000
    Bulgaria

    Active - Recruiting

  • Novartis Investigative Site

    Varna, 9000
    Bulgaria

    Active - Recruiting

  • Novartis Investigative Site

    Edmonton, Alberta T6G 1C3
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    Hamilton, Ontario L8L 3C3
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    London, Ontario N6H 5L5
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    Niagara Falls, Ontario L2H 1H5
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    Verdun, Quebec H4G 3E7
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    Quebec, G1V 4W2
    Canada

    Active - Recruiting

  • Novartis Investigative Site

    Brno, 60200
    Czechia

    Active - Recruiting

  • Novartis Investigative Site

    Plzen Bolevec, 32300
    Czechia

    Active - Recruiting

  • Novartis Investigative Site

    Prague 10, 100 34
    Czechia

    Site Not Available

  • Novartis Investigative Site

    Praha 10, 100 34
    Czechia

    Active - Recruiting

  • Novartis Investigative Site

    Toulon Cedex 9, Val De Marne 83800
    France

    Active - Recruiting

  • Novartis Investigative Site

    Bobigny Cedex, 93009
    France

    Active - Recruiting

  • Novartis Investigative Site

    Clermont Ferrand, 63003
    France

    Active - Recruiting

  • Novartis Investigative Site

    Grenoble, 38043
    France

    Active - Recruiting

  • Novartis Investigative Site

    La Rochelle, 17019
    France

    Active - Recruiting

  • Novartis Investigative Site

    La Tronche, 38700
    France

    Site Not Available

  • Novartis Investigative Site

    Nantes Cedex 1, 44093
    France

    Active - Recruiting

  • Novartis Investigative Site

    Nice, 06000
    France

    Active - Recruiting

  • Novartis Investigative Site

    Pierre Benite, 69495
    France

    Active - Recruiting

  • Novartis Investigative Site

    Rouen, 76031
    France

    Active - Recruiting

  • Novartis Investigative Site

    Frankfurt am Main, Hessen 60590
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Goettingen, Niedersachsen 37075
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Leipzig, Sachsen 04103
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Halle Saale, Sachsen-Anhalt 06120
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Bad Bentheim, 48455
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Berlin, 13353
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Bochum, 44791
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Dresden, 01307
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Frankfurt, 60590
    Germany

    Site Not Available

  • Novartis Investigative Site

    Freiburg, 79106
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Gottingen, 37075
    Germany

    Site Not Available

  • Novartis Investigative Site

    Halle, 06120
    Germany

    Site Not Available

  • Novartis Investigative Site

    Halle S, 06120
    Germany

    Site Not Available

  • Novartis Investigative Site

    Hamburg, 22391
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Heidelberg, 69120
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Luebeck, 23538
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Mainz, 55131
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Muenchen, 81377
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Muenster, 48149
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Osnabrueck, 49074
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Stade, 21682
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Tuebingen, 72076
    Germany

    Active - Recruiting

  • Novartis Investigative Site

    Debrecen, 4032
    Hungary

    Active - Recruiting

  • Novartis Investigative Site

    Kaposvar, 7400
    Hungary

    Active - Recruiting

  • Novartis Investigative Site

    Pecs, 7623
    Hungary

    Active - Recruiting

  • Novartis Investigative Site

    Ahmedabad, Gujarat 380016
    India

    Site Not Available

  • Novartis Investigative Site

    Bangalore, Karnataka 560004
    India

    Site Not Available

  • Novartis Investigative Site

    Belagavi, Karnataka 590010
    India

    Site Not Available

  • Novartis Investigative Site

    Mysore, Karnataka 570001
    India

    Site Not Available

  • Novartis Investigative Site

    Nagpur, Maharashtra 440015
    India

    Site Not Available

  • Novartis Investigative Site

    Nashik, Maharashtra 422101
    India

    Site Not Available

  • Novartis Investigative Site

    Bikaner, Rajasthan 334003
    India

    Site Not Available

  • Novartis Investigative Site

    Hyderabad, Telangana 500004
    India

    Site Not Available

  • Novartis Investigative Site

    Dehradun, Uttarakhand 248001
    India

    Site Not Available

  • Novartis Investigative Site

    Belgavi, 590010
    India

    Site Not Available

  • Novartis Investigative Site

    New Delhi, 110029
    India

    Site Not Available

  • Novartis Investigative Site

    Milano, MI 20122
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Rozzano, MI 20089
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Modena, MO 41124
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Roma, RM 00168
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Siena, SI 53100
    Italy

    Active - Recruiting

  • Novartis Investigative Site

    Ansan, Gyeonggi Do 425-801
    Korea, Republic of

    Active - Recruiting

  • Novartis Investigative Site

    Busan, 49241
    Korea, Republic of

    Active - Recruiting

  • Novartis Investigative Site

    Seoul, 03722
    Korea, Republic of

    Active - Recruiting

  • Novartis Investigative Site

    Muar, Johor 84000
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Ipoh, Perak 30450
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Petaling Jaya, Selangor Darul Ehsan 46150
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Kuala Lumpur, 59100
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Penang, 10990
    Malaysia

    Site Not Available

  • Novartis Investigative Site

    Pulau Pinang, 10990
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Wilayah Persekutuan, 62502
    Malaysia

    Active - Recruiting

  • Novartis Investigative Site

    Cuauhtemoc, Cdmx 06100
    Mexico

    Active - Recruiting

  • Novartis Investigative Site

    Zapopan, Jalisco 45190
    Mexico

    Active - Recruiting

  • Novartis Investigative Site

    Villahermosa, Tabasco 86035
    Mexico

    Active - Recruiting

  • Novartis Investigative Site

    Merida, Yucatan 97070
    Mexico

    Active - Recruiting

  • Novartis Investigative Site

    Amsterdam, 1105 AZ
    Netherlands

    Active - Recruiting

  • Novartis Investigative Site

    Utrecht, 3584
    Netherlands

    Active - Recruiting

  • Novartis Investigative Site

    Gdansk, 80-546
    Poland

    Active - Recruiting

  • Novartis Investigative Site

    Krosno, 38-400
    Poland

    Active - Recruiting

  • Novartis Investigative Site

    Poznan, 60-823
    Poland

    Active - Recruiting

  • Novartis Investigative Site

    Warszawa, 02-507
    Poland

    Active - Recruiting

  • Novartis Investigative Site

    Bardejov, 08501
    Slovakia

    Active - Recruiting

  • Novartis Investigative Site

    Kezmarok, 060 01
    Slovakia

    Active - Recruiting

  • Novartis Investigative Site

    Svidnik, 08901
    Slovakia

    Active - Recruiting

  • Novartis Investigative Site

    Trnava, 91702
    Slovakia

    Active - Recruiting

  • Novartis Investigative Site

    Cordoba, Andalucia 14004
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Granada, Andalucia 18014
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Barcelona, Catalunya 08035
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Valencia, Comunidad Valenciana 46015
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Pozuelo de Alarcon, Madrid 28223
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Las Palmas de Gran Canaria, 35010
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Madrid, 28046
    Spain

    Active - Recruiting

  • Novartis Investigative Site

    Geneve, 1205
    Switzerland

    Site Not Available

  • Novartis Investigative Site

    Geneve 14, 1211
    Switzerland

    Active - Recruiting

  • Novartis Investigative Site

    St Gallen, 9007
    Switzerland

    Site Not Available

  • Novartis Investigative Site

    Zuerich, 8091
    Switzerland

    Active - Recruiting

  • Novartis Investigative Site

    Taipei, 10002
    Taiwan

    Site Not Available

  • Novartis Investigative Site

    Taoyuan, 33305
    Taiwan

    Active - Recruiting

  • Novartis Investigative Site

    Bangkoknoi, Bangkok 10700
    Thailand

    Site Not Available

  • Novartis Investigative Site

    Songkhla, Hat Yai 90110
    Thailand

    Active - Recruiting

  • Novartis Investigative Site

    Khon Kaen, THA 40002
    Thailand

    Active - Recruiting

  • Novartis Investigative Site

    Bangkok, 10400
    Thailand

    Active - Recruiting

  • Novartis Investigative Site

    Chiang Mai, 50200
    Thailand

    Active - Recruiting

  • Novartis Investigative Site

    Istanbul, TUR 34098
    Turkey

    Active - Recruiting

  • Novartis Investigative Site

    Aydin, 09100
    Turkey

    Active - Recruiting

  • Novartis Investigative Site

    Denizli, 20070
    Turkey

    Active - Recruiting

  • Novartis Investigative Site

    Fatih / Istanbul, 34093
    Turkey

    Site Not Available

  • Novartis Investigative Site

    Fatih-Istanbul, 34093
    Turkey

    Active - Recruiting

  • Novartis Investigative Site

    Sakarya, 54290
    Turkey

    Active - Recruiting

  • Novartis Investigative Site

    Westbruy On Trym, Bristol BS10 5NB
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    Leeds, West Yorkshire LS9 7TF
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    Birmingham, B9 5SS
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    Oxford, OX3 7LE
    United Kingdom

    Active - Recruiting

  • Novartis Investigative Site

    Hanoi, 100000
    Vietnam

    Active - Recruiting

  • Novartis Investigative Site

    Ho Chi Minh, 7000
    Vietnam

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.